Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Details

Ressource 1Download: BIB_312BEA16C2AD.P001.pdf (2224.76 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_312BEA16C2AD
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Levodopa in the treatment of Parkinson's disease: an old drug still going strong.
Journal
Clinical Interventions In Aging
Author(s)
Poewe W., Antonini A., Zijlmans J.C., Burkhard P.R., Vingerhoets F.
ISSN
1178-1998[electronic], 1176-9092[linking]
Publication state
Published
Issued date
2010
Volume
5
Pages
229-238
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Abstract
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson's disease (PD). Compared with other available dopaminergic therapies, dopamine replacement with LD is associated with the greatest improvement in motor function. Long-term treatment with LD is, however, often complicated by the development of various types of motor response oscillations over the day, as well as drug-induced dyskinesias. Motor fluctuations can be improved by the addition of drugs such as entacapone or monoamine oxidase inhibitors, which extend the half-life of levodopa or dopamine, respectively. However, dyskinesia control still represents a major challenge. As a result, many neurologists have become cautious when prescribing therapy with LD. This review summarizes the available evidence regarding the use of LD to treat PD and will also address the issue of LD delivery as a critical factor for the drug's propensity to induce motor complications.
Keywords
Aged, Antiparkinson Agents/administration & dosage, Antiparkinson Agents/adverse effects, Dyskinesia, Drug-Induced/etiology, Humans, Levodopa/administration & dosage, Levodopa/adverse effects, Parkinson Disease/drug therapy
Pubmed
Web of science
Create date
08/03/2011 12:22
Last modification date
20/08/2019 13:16
Usage data